Dr. Richardson discusses an area of unmet need in relapsed/refractory multiple myeloma: how to identify treatment options for so-called "quad-refractory" patients.

Dr. Davies details the tools and technologies used to define and detect minimal residual disease, and discusses how to proceed once you know your patient's MRD status.

Dr. McCarthy explains the evolving recommendations for how and when to use herpes zoster vaccine in multiple myeloma patients, both active and newly diagnosed.

Dr. Raje discusses how we can expect to see more drugs and new combinations utilized in the upfront setting, as approvals in the relapsed/refractory setting increase.

Dr. Kumar reviews a range of patient- and disease-related factors to consider when choosing therapies for NDMM including; transplant eligibility, renal function, and presence of extramedullary disease

Dr. Raje explores options for treating smoldering multiple myeloma and explains how approaches in this precursor state hope to prevent progression to myeloma.

In this video, Dr. McCarthy discusses whether it may become standard of care to use antibiotic prophylaxis in certain patients with multiple myeloma.

Dr. Raje explains where denosumab fits in the treatment profile for bone disease in multiple myeloma.

Dr. Kumar reviews what the 2018 approval of daratumumab in combination with the VMP regimen in certain newly diagnosed multiple myeloma patients means for ongoing developments in four-drug regimens.

Dr. McCarthy explains the specific risks that patients with smoldering myeloma face, and what you need to look for in follow-up monitoring.